tbuckley/cabot-search huggingface dataset:
REPORT OF A FATAL CASE OF MALIGNANT EDEMA
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Family Practice
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Apolipoprotein B-100 Hopkins (arginine4019----tryptophan). A new apolipoprotein B-100 variant in a family with premature atherosclerosis and hyperapobetalipoproteinemia
Authors: J. A. Ladias
Journal: JAMA (1989)

A 43-year-old woman with severe coronary artery disease and hyperapobetalipoproteinemia was heterozygous for an abnormal<i>Msp</i>I apolipoprotein B (APOB) gene fragment because of the absence of the<i>Msp</i>I site around codon 4046 in exon 29 of the APOB gene. Using the polymerase chain reaction technique, 134 base pairs containing the mutant<i>Msp</i>I site were amplified, cloned, and sequenced. The mutation was a C to T transition, substituting tryptophan for arginine at amino acid position 4019 of the mature ApoB-100 protein. Seven relatives of the proband had the same mutation, which has been called "ApoB-100 Hopkins." Only three of seven relatives with the mutation had hyperapobetalipoproteinemia; one was borderline while two other relatives without the mutation had hyperapobetalipoproteinemia. Mutant low-density lipoprotein (LDL) was bound and degraded to a greater extent than normal LDL in cultured human fibroblasts. In conclusion, a new mutation, ApoB-100 Hopkins, was not linked to the hyperapobetalipoproteinemia phenotype, which also was segregating in this family. The increased affinity of this mutant LDL for the LDL receptor may be due to a specific effect of ApoB-100 Hopkins or to altered LDL size and composition. (<i>JAMA</i>. 1989;262:1980-1988)
Virology
Authors: Vernon Knight
Journal: JAMA (1989)

The authors define in the preface that their objectives in this text are to cover the entire field of virology—plant, insect, and bacterial as well as animal viruses. They also choose to consider in some detail the physical, chemical, and biochemical aspects of the structure and replication of viruses, especially as regards virus classification. The book, in one way, is a concise, annotated classification of viruses. By intent, there is little information about medical or disease aspects of virus infections. The figures are well chosen to illustrate important aspects of virus structure and replication. References are conveniently placed at the end of subsections of chapters. A number of references from 1985 to 1987 have been included as part of the revision for the second edition. The first edition is not available for comparison, but the content of this edition seems current. This book is well written, concise, and understandable. The
Response
Authors: R. C. DONEHOWER, D. A. NOE, A. HANTEL, E. K. ROWINSKY, B. L. VITO, W. P. MCGUIRE, D. S. ETTINGER
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Response Get access ROSS C. DONEHOWER, ROSS C. DONEHOWER The Johns Hopkins Oncology Center600 N. Wolfe St Baltimore, MD 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar DENNIS A. NOE, DENNIS A. NOE The Johns Hopkins Oncology Center600 N. Wolfe St Baltimore, MD 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar ALEXANDER HANTEL, ALEXANDER HANTEL The Johns Hopkins Oncology Center600 N. Wolfe St Baltimore, MD 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar ERIC K. ROWINSKY, ERIC K. ROWINSKY The Johns Hopkins Oncology Center600 N. Wolfe St Baltimore, MD 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar BARBARA L. VITO, BARBARA L. VITO The Johns Hopkins Oncology Center600 N. Wolfe St Baltimore, MD 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar WILLIAM P. MCGUIRE, WILLIAM P. MCGUIRE The Johns Hopkins Oncology Center600 N. Wolfe St Baltimore, MD 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar DAVID S. ETTINGER DAVID S. ETTINGER The Johns Hopkins Oncology Center600 N. Wolfe St Baltimore, MD 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 10, 22 May 1989, Pages 815–816, https://doi.org/10.1093/jnci/81.10.815-a Published: 22 May 1989
Council on Physical Therapy
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Grant Acknowledgment Omitted
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP)
Authors: H. M. Kantarjian, N. Gattermann, S. G. O’Brien, K. Bhalla, A. Hochhaus, F. Cervantes, L. Alland, O. Ottmann, F. Giles, P. Le Coutre
Journal: Journal of Clinical Oncology (2006)

6534 Background: AMN107 is a potent, highly selective, aminopyrimidine inhibitor which in vitro is 30-fold more potent than imatinib and active against 32/33 imatinib resistant Bcr-Abl mutations. Methods: This open-label study was designed to evaluate the safety and efficacy of AMN107 (400 mg bid) defined by hematologic/cytogenetic response (HR/CyR) rates in imatinib resistant or intolerant CP pts. Results: For this study which remains open to enrollment, preliminary data are reported for 67 pts including 39 (58%) with imatinib-resistant and 27 (40%) imatinib-intolerant CML (1 pt unknown). The median age was 62 (range 31–80) yrs and the median time from first diagnosis to treatment was 52 (range 5–279) mos. BCR-ABL mutations associated with imatinib resistance were detected in 11/17 (65%) pts at baseline. The median duration of AMN107 exposure was 129 (range 3–225) days. Treatment is ongoing for 50 (75%) pts with 17 (25%) pts discontinued (9 adverse events, 2 disease progression, 6 other). Major CyR was observed in 13 (19%) pts (6 complete, 7 partial), minor CyR was observed in 4 (17%) pts, and minimal CyR in 5 (7%) pts. Complete HR was reported in 35 of 42 (83%) pts without a baseline CHR. AE’s in ≥ 10% of pts were headache in 24 (36%) pts, fatigue in 21 (31%) pts (Gr 3/4 in 2 (3%)), pruritus in 19 (28.4%) pts (Gr 3/4 in 1 (2%)), rash in 18 (27%) pts (Gr 3/4 in 2 (3%)), nausea in 18 (27%) pts, diarrhea in 18 (27%) pts (Gr 3/4 in 1 (2%)), constipation in 11 (16%) pts, vomiting in 10 (15%) pts, thrombocytopenia in 10 (15%) pts (Gr 3/4 in 9 (13%)), anemia in 10 (14.9%) pts (Gr 3/4, 1 (2%)), neutropenia in 9 (13%) pts (Gr 3/4 in 8 (12%)), bone pain, muscle spasms, arthralgia, peripheral edema in 8 (12%) pts each, abdominal pain and myalgia in 7 (10%) pts each (Gr 3/4 in 1 (2%) each), and dyspnea in 7 (10%) pts. No deaths occurred. Conclusions: AMN107 has clinical activity and an acceptable safety and tolerability in pts with imatinib-resistant or intolerant CML-CP. [Table: see text]
Bacteremic Pseudomonas Pneumonia
Authors: Paul B. lannini
Journal: JAMA (1974)

We have studied 20 cases of bacteremic Pseudomonas aeruginosa pneumonia and have reviewed 29 cases recorded in the literature. Analysis of the accumulated data indicates that bacteremic Pseudomonas pneumonia is invariably associated with conditions that impair host defenses, especially hematologic or reticuloendothelial malignant neoplasms, and it is almost universally fatal even after therapy with appropriate antimicrobials. A chest roentgenogram that simulates pulmonary vascular congestion in the presence of normal central venous pressure may be an important clue to the existence of this type of pneumonia. (<i>JAMA</i>230:558-561, 1974)
Influence of Adherence to Treatment and Response of Cholesterol on Mortality in the Coronary Drug Project
Journal: New England Journal of Medicine (1980)

The Coronary Drug Project was carried out to evaluate the efficacy and safety of several lipid-influencing drugs in the long-term treatment of coronary heart disease. The five-year mortality in 1103 men treated with clofibrate was 20.0 per cent, as compared with 20.9 per cent in 2789 men given placebo (P = 0.55). Good adherers to clofibrate, i.e., patients who took 80 per cent of more of the protocol prescription during the five-year follow-up period, had a substantially lower five-year mortality than did poor adherers to clofibrate (15.0 vs. 24.6 per cent; P = 0.00011). However, similar findings were noted in the placebo group, i.e., 15.1 per cent mortality for good adherers and 28.3 per cent for poor adherers (P = 4.7x10-16). These findings and various other analyses of mortality in the clofibrate and placebo groups of the project show the serious difficulty, if not impossibility, of evaluating treatment efficacy in subgroups determined by patient responses (e.g., adherence or cholesterol change) to the treatment protocol after randomization.
Renal Lithiasis
Authors: Stephen M. Krane
Journal: New England Journal of Medicine (1962)

A GREAT deal can be accomplished to prevent the formation of renal stones. Indeed, such prophylaxis is as important as the surgical removal of the stone itself. It is essential for the medical management of patients with renal calculi to consider the composition of the stone and to be aware of the conditions that predispose to calculus formation. As a general rule, calculi are formed because the concentration of a particular solute (or solutes) in the urine exceeds the limits of solubility at a particular pH. The concentration of solute may be too high because the total amount excreted is . . .
Pericardial Echocardiography
Authors: LEWIS SASSÉ
Journal: Annals of Internal Medicine (1977)

Letters and Corrections1 November 1977Pericardial EchocardiographyLEWIS SASSÉ, M.D., F.A.C.P.LEWIS SASSÉ, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-87-5-635_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Millman and colleagues maintain, in "Pericardial Tumor or Fibrosis Mimicking Pericardial Effusion by Echocardiography" (Ann Intern Med86:434-436, 1977), that their echocardiograms "represent true findings and not 'false-positives' because they were taken in standard position and were taken using the usual method for evaluation of the pericardium." However, the main criterion used was a sonolucent space between the apparent posterior epicardium and pericardium according to a 1970 reference (1). More recent publications have stressed the need for sweeping the transducer from the posterior left ventricular wall to the posterior left atrial wall where the sonolucence due to...References1. FEIGENBAUM H: Echocardiography diagnosis of pericardial effusion. Am J Cardiol 26:475-479, 1970 CrossrefMedlineGoogle Scholar2. GRAMIAKWAAG RR: Cardiac Ultrasound. St. Louis, C.V. Mosby Company, 1975, p. 112 Google Scholar3. GREENEKLEIDNAIDU DSS: Unusual echocardiographic manifestation of pericardial fluid. Am J Cardiol 39:112-115, 1977 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: LEWIS SASSÉ, M.D., F.A.C.P. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 November 1977Volume 87, Issue 5Page: 635-635KeywordsEchocardiographyFibrosisPericardium ePublished: 1 December 2008 Issue Published: 1 November 1977 PDF downloadLoading ...
The Law of the Morphology or Metamorphosis of the Textures of the Human Body
Authors: W. Addison
Journal: BMJ (1847)

THE'TEXTURES.on the inferior margins, and on the surface of the lobes, must be taken as collateral proofs of the existence of some long-standing affection of the pulmonary organs, attended most probably by violent expiratory efforts, as in coughing; but the subject and patho.logical conditions of emphysema I propose to treat of on some other occasion.
On Colotomy
Authors: C. Heath
Journal: BMJ (1881)

IN a lecture on the enlargement of ophthalmoscopic images, by Dr. Landolt, which appeared in the number of the BRITISH MEDICAL JOURNAL for January 3rd, i88o, the author says that the results obtained by the direct method are only relatively exact; " for, unfortunately, the fundus oculi does not present any object of constant size, or directly measurable".Now, it so happens that, by a particular application of the "law of Bravais`*, an image of known magnitude and constant size (say of a grating) can be projected on the fundus oculi, and seen by the direct method, simultaneously with any object there which it may be required to measure.The "law of Bravais", shortly stated, is as follows.When the distance between two dioptric systems is equal to the sum of their principal foci, parallel incident rays emerge from
Environmental Aspects of Injury and Disease: Liver and Bile Ducts
Authors: Edward S. Reynolds
Journal: Environmental Health Perspectives (1977)

Evolutionary processes have not yet developed specific and safe ways to detoxify all chemical species new to our environment. Indeed, some are transformed and/or conjugated by the liver into more toxic species. Environmental factors can modulate hepatic enzyme systems. Particularly responsive are the mixed function oxidases, which initiate the transformation of many xenobiotics to excretable species via reactions which generate electrophilic intermediates such as free radicals, epoxides and aldehydes. Unless these reactive metabolites are rapidly removed by subsequent detoxification reactions or by endogenous defense systems, destructive cytotoxic reactions can be triggered or cell constitutents “attacked” thereby causing either acute injury and/or more latent molecular injury to long chain biopolymers resulting in chromatin damage, or tumors. In vitro systems using purified, specialized cell fractions may be of considerable value in defining metabolic processes, but the results must be relevant to in vivo conditions. Although human liver is peculiarly resistant to tumorigenesis, liver microsomes (isolated endoplasmic reticulum) are extensively used as biological activators for in vitro mutagenicity test systems. The in vivo defense system of liver cells must be exceptionally efficient! Reactive metabolites generated in liver may be stable enough to migrate and cause injury to other tissues or organ systems. It is important to characterize metabolic pathways of toxic xenobiotics, subsequent molecular sites or modes of injury, and factors which depress or augment cellular defense systems including the biliary system responsible for the excretion of many xenobiotics. Only then can techniques or treatments be developed to screen individuals for risk to specific groups of xenobiotics, to protect those exposed, and to treat those injured.
Cardiac arrest following fluorescein angiography
Authors: E. E. Cunningham
Journal: JAMA (1979)

THE INTRAVENOUS (IV) use of fluorescein as an ophthalmologic tool is generally considered a safe procedure with few adverse side effects. Two cases of cardiac arrest<sup>1</sup>and one case of fatal myocardial infarction,<sup>2</sup>however, have been reported following IV fluorescein use. Deglin et al<sup>3</sup>reported the first case of well-established myocardial infarction associated with fluorescein injection. We observed a case of fatal cardiac arrest following fluorescein angiography. <h3>Report of a Case</h3> A 61-year-old man with a history of chronic stable angina since 1968 was referred to our hospital on June 9, 1977, for evaluation of accelerated angina of two weeks' duration. He had a history of hypertension for 15 years, and diabetes for four years; both diseases were well controlled. He had had a myocardial infarction in 1968. The patient was well developed, well nourished, and in no acute distress. His blood pressure was 150/70; pulse rate, 70
Gynecologic Oncology
Authors: Thomas H. Green
Journal: JAMA (1976)

This superbly written and beautifully illustrated monograph on gynecologic oncology admirably accomplishes its avowed twofold purpose. First, it serves as an excellent overview of the clinical approach to the management of malignant disease of the female pelvic organs. This basic information about each of the gynecologic malignancies is of great importance to any physician, regardless of his specialty, who is caring for women and who strives to achieve early recognition and diagnosis of preclinical as well as symptomatic gynecologic tumors. Second, it contains a wealth of helpful information for the specialist actually involved in the care of women with pelvic malignancies. Fundamentally, it presents the vast experience and sound and tested diagnostic and therapeutic techniques and programs currently employed at the M.D. Anderson Hospital and Tumor Institute in Houston. As such, it represents the latest thinking and practice on the part of the various departments involved— gynecologic surgery, radiotherapy, diagnostic
Section B. ERGOMETRY AND MUSCLE PHYSIOLOGY
Authors: K Caesar, D Jeschke, H Oldershausen, S Oseid, L Hermansen, J Fric, H Mellerowicz, U Hd, R Carrow2, W Heusner3, W Van Huss4, Michio Ikai
Journal: British Journal of Sports Medicine (1973)

Interval training of the flexor and extensor muscles of the right forearm was conducted with 11 young, healthy persons.Before the beginning, after 6 weeks and after 12 weeks of training, measurements were made at rest and immediately after a standardised exercise in supine position.Simultaneously venous and arterial blood were taken from the trained forearm, and lactate, pyruvate and P02 were determined.The blood flow was registered with a segment plethysmograph.After training, the blood flow at rest and immediately after standardised exercise is not significantly changed.The venous lactate concentration of the trained forearm and the arterio-venous difference of lactate increases more with the same work load after 6 and 12 weeks of training than before.The pyruvate concentration increases less after muscle work.The lactate pyruvate quotient in venous blood of the exercising forearm increases with progress of the isolated training.The venous oxygen pressure is not altered compared to the values before training.The arterio-venous difference of the oxygen pressure declines less after training exercise.The metabolic changes are explained by improved glycolytic performance of the trained muscle cell.The improved glycolysis probably precedes the alteration of the blood flow in this kind of short interval-training of isolated muscle groups.control 6 weeks training 12 weeks training p.